Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1599-1607

  Oh, Chun Taek ^a   Moon, Cheol ^b   Park, Ok Kyu ^c   Kwon, Seung Hae ^c   Jang, Jichan ^a  

^a Institute Pasteur Korea   (South Korea)

^b Semyung University   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Combination therapy; Drug discovery; Invertebrate model; Mycobacterium abscessus disease

Indexed keywords

AMIKACIN; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; GREEN FLUORESCENT PROTEIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; DRUG EFFICACY; DRUG POTENCY; FEMALE; FLUORESCENCE; IN VIVO STUDY; LIFESPAN; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; SURVIVAL RATE; ANIMAL; BACTERIAL LOAD; DISEASE MODEL; DROSOPHILA; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; MICROBIOLOGY; MORTALITY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; REPORTER GENE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GENES, REPORTER; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS;

EID: 84903125505     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku024     Document Type: Article

References (23)

1. Bartlett JG, Auwaerter PG, Pham PA. Johns Hopkins ABX Guide: Diagnosis and Treatment of Infectious Diseases. 3rd edn. Burlington, MA: Jones and Bartlett Learning, 2012; 284-5.
2. Nessar R, Cambau E, Reyrat JM et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67: 810-8.
3. Furuya EY, Paez A, Srinivasan A et al. Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008; 46: 1181-8.
4. Shanmugham B, Pan A. Identification and characterization of potential therapeutic candidates in emerging human pathogen Mycobacterium abscessus: a novel hierarchical in silico approach. PLoS One 2013; 8: e59126.
5. Fraud S, Hann AC, Maillard JY et al. Effects of ortho-phthalaldehyde, glutaraldehyde and chlorhexidine diacetate on Mycobacterium chelonae and Mycobacterium abscessus strains with modified permeability. J Antimicrob Chemother 2003; 51: 575-84.
6. Ripoll F, Pasek S, Schenowitz C et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
7. Park S, Kim S, Park EM et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 2008; 23: 49-52.
8. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 2008; 52: 2019-26.
9. Lyu J, Jang HJ, Song JW et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011; 105: 781-7.
10. Chopra S, Matsuyama K, Hutson C et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 2011; 66: 1533-6.
11. Matteelli A, Carvalho AC, Dooley KE et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-58.
12. Oh CT, Moon C, Jeong MS et al. Drosophila melanogaster model for Mycobacterium abscessus infection. Microbes Infect 2013; 15: 788-95.
13. Nessar R, Reyrat JM, Murray A et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011; 66: 1719-24.
14. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
15. Sacksteder KA, Protopopova M, Barry CE 3rd et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 2012; 7: 823-37.
16. Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
17. Huang CW, Chen JH, Hu ST et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013; 41: 218-23.
18. Shen GH, Wu BD, Hu ST et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35: 400-4.
19. Mukherjee T, BoshoffH, Barry CE 3rd. Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 2012; 67: 252-3.
20. Wallace RJ Jr, Brown-Elliott BA, Ward SC et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764-7.
21. Oh CT, Moon C, Choi TH et al. Mycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment. J Antimicrob Chemother 2013; 68: 601-9.
22. Stout JE, Floto RA. Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others. Am J Respir Crit Care Med 2012; 186: 822-3.
23. Cremades R, Santos A, Rodríguez JC et al. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 2009; 15: 46-8.